FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Zane Ellen M, a director at Boston Scientific Corp (NYSE:BSX), recently sold 13,586 shares of the company’s common stock. The transaction, executed on February 24, 2025, was conducted under a pre-established Rule 10b5-1 trading plan. The healthcare equipment giant, currently valued at $153.75 billion, has seen its stock surge nearly 56% over the past year, according to InvestingPro data. The shares were sold at a weighted average price of $104.23, with the sale generating a total value of approximately $1.42 million.
Following this sale, Zane Ellen M retains ownership of 34,944 shares in Boston Scientific. The transaction was part of a series of trades executed at prices ranging from $103.88 to $104.545 per share.
In other recent news, Boston Scientific Corporation has reported significant developments that are drawing attention from investors. The company has seen an upgrade in its credit rating to ’A-’ from both S&P Global Ratings and Fitch Ratings, reflecting its strong operational performance and robust cash flow. Boston Scientific’s revenue reached $16.7 billion in 2024, marking a 17.6% increase from the previous year, driven by successful product launches such as Farapulse and Watchman devices. Looking ahead, the company has provided strong guidance for 2025, with expectations of 11-13% revenue growth and improving EBITDA margins.
Analysts from Stifel and RBC Capital Markets have responded positively to Boston Scientific’s performance and future prospects. Stifel raised its price target to $120, maintaining a Buy rating, while RBC Capital increased its target to $116, with an Outperform rating. These adjustments are based on the company’s recent financial results and potential for continued growth in high-demand markets. Additionally, Boston Scientific announced that board member Charles J. Dockendorff will not seek re-election, prompting a review of the board’s composition.
The company’s strategic focus on innovation and acquisitions is expected to continue, with plans for $4 billion-$5 billion in annual acquisitions. This approach aligns with Fitch’s expectation of maintaining a leverage target of 2.25x-2.5x. Boston Scientific’s financial policies remain conservative, with projections of solid free cash flow and liquidity supported by a $2.75 billion revolving credit facility. These developments underscore Boston Scientific’s strong position in the MedTech sector and its potential for sustained growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.